SCHEMBL4052391

SCHEMBL4052391

COc1cc(-c2nc3ccc(-c4ccccc4C(F)(F)F)cc3o2)cc(OC)c1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.49
HPGD P15428 5/20 0.48
GAA P10253 2/20 0.48
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 4/20 0.47
HSD17B10 Q99714 3/20 0.47
PTGS2 P35354 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.43
PDE7A Q13946 1/20 0.43
PDE3A Q14432 1/20 0.43
BACE1 P56817 1/20 0.43
GPR119 Q8TDV5 1/20 0.43
PDE4C Q08493 2/20 0.42
UTRN P46939 1/20 0.42
PIK3R1 P27986 1/20 0.42
PIK3CA P42336 1/20 0.42
TRPA1 O75762 1/20 0.41
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4059707 0.90 NPC1 (0.62) NPC1HPGDKDM4EALDH1A1HSD17B10
SCHEMBL4053287 0.88 GPR119 (0.54) NPC1HSD17B10PTGS2BACE1GPR119
SCHEMBL4053451 0.85 NPC1 (0.52) NPC1KDM4EALDH1A1SMN1; SMN2BACE1
SCHEMBL4057895 0.85 HDAC6 (0.52) NPC1HPGDKDM4EALDH1A1HSD17B10
SCHEMBL4051500 0.83 NPC1 (0.54) NPC1HPGDKDM4EALDH1A1HSD17B10
SCHEMBL4058082 0.82 BACE1 (0.51) NPC1HPGDGAAKDM4EALDH1A1
SCHEMBL4053408 0.79 NPC1 (0.51) NPC1HPGDKDM4EALDH1A1HSD17B10
SCHEMBL4051587 0.77 VSIR (0.51) NPC1HPGDKDM4EALDH1A1BACE1
SCHEMBL4057762 0.77 BACE1 (0.46) KDM4EBACE1UTRNPIK3R1PIK3CA
SCHEMBL4059846 0.76 P2RY14 (0.47) NPC1SMN1; SMN2BACE1GPR119PIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NPC1 4740/4885HPGD 3915/4885GAA 3196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.